Video

Dr. Campbell on the Guidelines for the Management of Kidney Cancer

Author(s):

Steven Campbell, MD, PhD

In Partnership With:

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.

The main objective of these guidelines was to provide recommendations for the evaluation and management of localized kidney cancer, explains Campbell.

These guidelines are an evidence-based approach to the evaluation, counseling and selective utilization of renal mass biopsy. Additionally, each of the management options are reviewed, states Campbell.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Related Content
Belzutifan Plus Cabozantinib in RCC | Image Credit: © Katsyarina - stock.adobe.com
January 9th 2025

First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Christopher J. Logothetis, MD, of The University of Texas MD Anderson Cancer Center
December 27th 2024

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology

Aaron Gerds, MD
December 16th 2024

Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis